Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bactericidal Activity and Resistance Development Profiling of Dalbavancin

13 Jan 2007

Abstract excerpt

ABSTRACT Dalbavancin, a semisynthetic lipoglycopeptide being developed for the treatment of skin and skin structure infections (SSSIs), has a half-life of 5 to 7 days in humans and offers promise for a convenient weekly dosing regimen. We studied the in vitro bactericidal activity of dalbavancin against target organisms, using the concentrations that are maintained in human blood with the proposed dosage regimen....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Peptides and Activities
Share to Antimicrobial Resistance in Staphylococcus
Share to Biochemical and Structural Characterization

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17220411
DOI: 10.1128/aac.00620-06

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bactericidal Activity and Resistance Development Profiling of DalbavancinPMID 17220411Read ↗

Dalbavancin-resistant Staphylococcus epidermidis in vivo selection following a prosthetic joint infection: phenotypic and genomic characterizationSemantic proximity Read ↗

In Vivo Pharmacodynamic Activity of the Glycopeptide DalbavancinSemantic proximity Read ↗

Emergence of dalbavancin non-susceptible methicillin-resistant Staphylococcus epidermidis (MRSE) in a patient treated with dalbavancin prolonged therapy: Case report, therapeutic drug monitoring and genomic characterization.Semantic proximity Read ↗

Emerging resistance inStaphylococcus epidermidisduring dalbavancin exposure: a case report andin vitroanalysis of isolates from prosthetic joint infectionsSemantic proximity Read ↗

Off-label use of dalbavancin in children: a case seriesSemantic proximity Read ↗

Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registrySemantic proximity Read ↗

Cost-Utility of Dalbavancin as a Treatment Option for Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in CanadaSemantic proximity Read ↗

Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensSemantic proximity Read ↗

New Gram-Positive Agents: the Next Generation of Oxazolidinones and LipoglycopeptidesSemantic proximity Read ↗

Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococciSemantic proximity Read ↗

Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype.Semantic proximity Read ↗

Redox-active compounds with a history of human use: antistaphylococcal action and potential for repurposing as topical antibiofilm agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.